Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Last trade$0.8589
Day change-$0.0649 (-7.03%)
Day range$0.812 – $0.974
Volume1,929,336
Market cap$112M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$111.1M
Price / earnings
—
Price / book
0.38×
Price / sales
504.99×
EV / sales
325.63×
EV / EBITDA
-0.56×
Profitability
Earnings per share
-$1.02
Return on assets
-33.61%
Return on equity
-41.71%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
5.18×
Quick ratio
5.18×
Cash ratio
1.04×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$138.84M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CATX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$20K
$81K
$76K
$43K
$209K
$290K
$342K
$234K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$20K
$81K
$76K
$43K
$209K
$290K
$342K
$234K
Selling, general and administrative
$8.27M
$7.8M
$6.99M
$6.95M
$7.73M
$7.71M
$7.84M
$8.25M
Research and development
$26.07M
$21.54M
$21.37M
$32.92M
$20.34M
$16.62M
$14.33M
$12.88M
Total operating expenses
$34.34M
$29.34M
$28.36M
$39.88M
$28.07M
$24.33M
$22.17M
$45.19M
Operating income
-$34.32M
-$29.26M
-$28.28M
-$39.83M
-$27.86M
-$24.04M
-$21.83M
-$44.96M
Interest expense
-$157K
-$71K
-$105K
-$64K
-$65K
-$119K
-$128K
$73K
Income before taxes
-$32.44M
-$26.98M
-$26.19M
-$38.28M
-$25.97M
-$22M
-$18.18M
-$42.27M
Income taxes
$0
$0
$0
-$793K
$0
$0
$0
-$2.1M
Net income
-$32.44M
-$26.79M
-$26.19M
-$37.49M
-$25.97M
-$21.49M
-$18.18M
-$40.17M
Net income attributable to common shareholders
-$32.44M
-$26.79M
-$26.19M
-$37.49M
-$25.97M
-$21.49M
-$18.18M
-$40.17M
EBITDA
-$33.13M
-$28.12M
-$27.16M
-$38.82M
-$27.09M
-$23.31M
-$21.1M
-$20.19M
Basic earnings per share
-$0.27
-$0.22
-$0.25
-$0.50
-$0.35
-$0.29
-$0.25
-$0.57
Diluted earnings per share
-$0.27
-$0.22
-$0.25
-$0.50
-$0.35
-$0.29
-$0.25
-$0.57
Recent news
Company coverage with links to the original publishers.
Perspective Therapeutics announced positive Phase 1/2a trial data for bamzireotide navoxetan (VMT-α-NET) in neuroendocrine tumor patients. The drug demonstrated durable disease control with 75% progression-free survival at 18 months in GEP-NET patients with SSTR2-positive target lesions, compared to 65% for an approved competitor. The treatment was well-tolerated with no dose-limiting toxicities or treatment discontinuations. The company plans an end-of-Phase 2 meeting with the FDA in Q1 2027 and aims to initiate Phase 3 studies in 2027.
Profound Medical (PROF) surged 21.7% following strong preliminary Q3 2026 revenue guidance of $9.8-10 million, representing 85-89% year-over-year growth and 45-47% above analyst consensus. The company expects gross margins exceeding 70%, signaling improved commercial momentum. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock's momentum may not sustain without further positive estimate revisions.
Perspective Therapeutics announced it will present updated clinical data from all three of its radiopharmaceutical programs at the 2026 ASCO Annual Meeting. Key highlights include one new responder in the [212Pb]VMT01 melanoma monotherapy cohort (29% response rate), advancement of [212Pb]PSV359 to Cohort 3 with favorable safety profile, and continued deepening of responses in [212Pb]VMT-α-NET for neuroendocrine tumors. All programs demonstrated good tolerability with no dose-limiting toxicities reported.
The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a first-in-class 212Pb-radiopharmaceutical targeting SSTR2-positive neuroendocrine tumors. The trial showed a 43% objective response rate in Cohort 2 patients, with no dose-limiting toxicities or serious treatment-related complications. The company plans to submit clinical evidence for regulatory engagement in 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.